Cingulate

Cingulate Net Change in Cash

The Net Change in Cash of Cingulate (CING) as of Nov 11, 2026 is -1.26 M USD. In the previous year, Net Change in Cash was 12.16 M USD — a change of -110.35% (lower).

Net Change in Cash

-1.26 MUSD

YoY

-110.35%

Last updated:

Net Change in Cash of Cingulate is 2025 -1.26 M USD. Net Change in Cash of Cingulate was 2024 12.16 M USD. It decreases by -110.35% lower compared to the previous year.

The Cingulate Net Change in Cash history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Change in Cash
Date
Net Change in Cash
Jan 1, 2019
-644,741.00 USD
Jan 1, 2020
779,202.00 USD
Jan 1, 2021
15.30 M USD
Jan 1, 2022
-11.14 M USD
Jan 1, 2023
-5.30 M USD
Jan 1, 2024
12.16 M USD
Jan 1, 2025
-1.26 M USD
The Cingulate Net Change in Cash history
YEARNet Change in CashYoY
-1.26 MUSD-110.35%
12.16 MUSD-329.25%
-5.30 MUSD-52.37%
-11.14 MUSD-172.81%
15.30 MUSD+1,862.92%
779,202.00USD-220.86%
-644,741.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cingulate Stock analysis

What does Cingulate do? Cingulate Inc is a US-based biopharmaceutical company headquartered in Kansas City, Kansas, that focuses on the development, manufacturing, and commercialization of pharmaceutical products. The firm utilizes its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles designed to improve the lives of patients suffering from commonly diagnosed conditions. The company specifically targets the treatment of attention deficit/hyperactivity disorder (ADHD) through its innovative approach to drug delivery. The firm is currently developing two lead product candidates, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). These drug candidates both contain three releases of an active pharmaceutical ingredient combined into one small tablet dosage form. By employing this technology, Cingulate Inc aims to provide effective treatment options for ADHD across three core patient segments: children aged 6-12, adolescents aged 13-17, and adults aged 18 and older. Cingulate is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cingulate stock

Net Change in Cash of Cingulate is -1.26 M USD in 2025.

Net Change in Cash of Cingulate changed from 12.16 M USD to -1.26 M USD, representing a -110.35% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Change in Cash Cingulate since 2006 – with annual values, charts, and detailed analysis.

Net change in cash is the total change in cash and equivalents during the period, combining operating, investing, and financing cash flows.

Net Change in Cash's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Change in Cash's Cingulate historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Cingulate

All Key Metrics — Cingulate